Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

RA Capital Management Discloses New Stake in SANUWAVE Health Inc. (SNWV); Boosts Position in pSivida Corp. (PSDV)

In two recent filings with the U.S. Securities and Exchange Commission, Peter Kolchinsky’s RA Capital Management has revealed a new position in SANUWAVE Health Inc. (OTCBB:SNWV) and  raising its stake in pSivida Corp. (NASDAQ:PSDV). In the first company, the fund has reported a 9.9% passive stake, which contains around 4.67 million shares.

Peter Kolchinsky

SANUWAVE Health Inc. (OTCBB:SNWV) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. On March 18, the company said, in a statement that it closed a private placement with institutional and select accredited investors, led by RA Capital, raising total gross proceeds of $10.1 million. Included in the total is the conversion into equity, under the same terms as the private placement, of $815,000 worth of convertible notes with existing shareholders, including a member of the management team.

SANUWAVE Health issued common stock, and preferred stock convertible into common stock, totaling 20.2 million shares of common stock on a fully converted basis at a price of $0.50 per share. Also, it issued to the investors warrants to purchase up to 25.25 million shares of common stock at an exercise price of $0.50 and 15.15 million shares of common stock at $1.50. The warrants are immediately exercisable and have an exercise term of five years and one year, respectively.

Ra Capital’s stake in pSivida Corp. (NASDAQ:PSDV) amasses 8.8% of the company’s stock. According to the filing, the fund owns around 2.56 million shares of the company, up from 1.19 million shares held earlier.

Recently, pSivida Corp. (NASDAQ:PSDV) announced that RA Capital entered into a securities purchase agreement with the company to invest about $7.0 million in a registered direct offering through the sale of a total of 1.7 million shares of the company’s common stock at a per share price of $4.11.

pSivida provides miniaturized, sustained-release drug delivery products. One of the largest shareholders of the company is Thomas Ellis and Todd Hammer’s North Run Capital, which disclosed owning 2.14 million shares as at the end of 2013.

Boston-based RA Capital is a healthcare crossover fund that invests in development-stage private and public drug, medical device, and diagnostic companies. Last week, it revealed a new 6.2% passive stake in Repros Therapeutics Inc (NASDAQ:RPRX), holding 1.44 million shares of the company’s common stock.

In February, RA Capital disclosed owning 2.43 million shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), equivalent to 14.6% of the common stock. In addition, the fund initiated a 7.2% passive stake in Furiex Pharmaceuticals Inc (NASDAQ:FURX), the position amassing 750,000 shares. In January, Mr. Kolchinsky’s fund reported selling a total of 300,000 shares of Derma Sciences Inc (NASDAQ:DSCI).

Disclosure: none

Recommended Reading:

Buffett’s Berkshire Converts Notes Worth $56 Mln into Shares of USG Corporation (USG)

Hedge Fund News: David Einhorn, Edward Lampert & Carl Icahn

Berkshire Partners’ Subsidiary Stockbridge Partners Surges Stake in RealPage, Inc. (RP)

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...